Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab higher doses in wet AMD
NCT00533520Phase 4Completed
- Start
- Sep 2007
- Primary completion
- Nov 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration. Started Sep 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00533520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533520.